Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1600 1641 1644
This examiner grants 63% of resolved cases
Michael Edward Szperka is an examiner in Tech Center 1600 and Art Unit 1600. He has 949 resolved cases and an allowance rate of 62.8%. This is a solid rate, indicating a majority of cases are successful. The interview lift is 36.8%, which is a very high figure and suggests that interviews are a highly effective strategy.
The median days to allowance is 1119. This timeline is a standard benchmark for prosecution in Art Unit 1600. The 36.8% interview lift is a key piece of information for practitioners, as it significantly improves the 62.8% baseline allowance rate. With 949 resolved cases, these statistics offer a reliable view of the environment in Tech Center 1600. The 1119-day median is a critical metric for managing client expectations and planning for the duration of the examination process.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18242868 | FACTOR X BINDERS ENHANCING FX ACTIVATION | Final Rejection | Novo Nordisk A/S |
| 18249991 | NATURAL KILLER CELLS WITH ENHANCED ACTIVITY | Non-Final OA | The Regents of the University of California |
| 18048386 | THERAPIES AND METHODS TO TREAT TLR2-MEDIATED DISEASES AND DISORDERS | Non-Final OA | The Regents of the University of California |
| 17040476 | TRANS-ANTIGEN TARGETING IN HETEROGENEOUS CANCERS AND METHODS OF USE THEREOF | Final Rejection | The Regents of the University of California |
| 17868422 | SYSTEMS AND METHODS FOR MONITORING PLATELET ACTIVATION | Final Rejection | The Regents of the University of Michigan |
| 18247198 | METHODS FOR REDUCING HOST CELL PROTEIN CONTENT IN ANTIBODY PURIFICATION PROCESSES AND ANTIBODY COMPOSITIONS HAVING REDUCED HOST CELL PROTEIN CONTENT | Non-Final OA | Eli Lilly and Company |
| 18433619 | CHIMERIC IGG-FC-BINDING LIGAND POLYPEPTIDE AND USES THEREOF FOR IGG AFFINITY PURIFICATION | Non-Final OA | Roche Diagnostics Operations, Inc. |
| 18655058 | FACTOR XI ANTIBODIES AND METHODS OF USE | Non-Final OA | NOVARTIS AG |
| 18391485 | METHODS OF TREATING CHRONIC SPONTANEOUS URTICARIA USING LIGELIZUMAB | Non-Final OA | Novartis AG |
| 18060215 | COMPOSITIONS AND METHODS FOR PURIFYING ALPHA-1 ANTITRYPSIN USING PEPTIDE LIGANDS | Final Rejection | North Carolina State University |
| 18250106 | COMBINATION VACCINE FOR PROTECTING SWINE AGAINST VARIOUS DISORDERS | Final Rejection | Intervet Inc. |
| 18556998 | METHODS FOR REDUCING LOW MOLECULAR WEIGHT SPECIES OF RECOMBINANTLY-PRODUCED PROTEINS | Non-Final OA | AMGEN RESEARCH (MUNICH) GmbH |
| 18555910 | METHOD AND COMPOSITION | Non-Final OA | Oxford University Innovation Limited |
| 18707096 | T CELL IMMUNOTHERAPY FOR HEMATOLOGIC MALIGNANCIES HAVING AN SF3B1 MUTATION | Non-Final OA | FRED HUTCHINSON CANCER CENTER |
| 18532709 | COMPLEMENT FACTOR H ANTIBODIES | Non-Final OA | Duke University |
| 18482187 | POLYPEPTIDES BINDING ADAMTS5, MMP13 AND AGGRECAN | Non-Final OA | ABLYNX NV |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy